Abstract

BONO, Julio; RICARTE-BRATTI, Juan P.  and  BARCUDI, Raúl. Is the NSTEACS pretreatment recommended by the guidelines what reflects the real world?. Arch. Cardiol. Méx. [online]. 2023, vol.93, n.4, pp.476-481.  Epub Nov 28, 2023. ISSN 1665-1731.  https://doi.org/10.24875/acm.22000198.

The appropriate time for the administration of P2Y12 inhibitors in patients with non-ST elevation acute coronary syndrome has been the subject of debate for two decades. The current recommendations of the European guidelines suggest administering acetylsalicylic acid and waiting for the coronary angiography and once the anatomy is known, adding a P2Y12 inhibitor only in those cases in which an early interventional strategy is scheduled. However, in the real world, the strategy to perform pretreatment or not is more complex. There is uncertainty regarding whether the patient can access a coronary angiography within 24 hours. In this scenario, pretreatment upon admission of intermediate or high-risk patients could be an option if it is not studied with catheterization within 2 to 4 hours of admission, previously analyzing the patient's ischemic and bleeding risk. Large-scale studies comparing these two options are still lacking.

Keywords : Platelet antiaggregants; Acute coronary syndrome; Antithrombotics; Pretreatment.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )